This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log in
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 4;16(1):7.
doi: 10.1186/s13040-023-00325-1.

Signature literature review reveals AHCY, DPYSL3, and NME1 as the most recurrent prognostic genes for neuroblastoma

Affiliations

Signature literature review reveals AHCY, DPYSL3, and NME1 as the most recurrent prognostic genes for neuroblastoma

Davide Chicco et al. BioData Min. .

Abstract

Neuroblastoma is a childhood neurological tumor which affects hundreds of thousands of children worldwide, and information about its prognosis can be pivotal for patients, their families, and clinicians. One of the main goals in the related bioinformatics analyses is to provide stable genetic signatures able to include genes whose expression levels can be effective to predict the prognosis of the patients. In this study, we collected the prognostic signatures for neuroblastoma published in the biomedical literature, and noticed that the most frequent genes present among them were three: AHCY, DPYLS3, and NME1. We therefore investigated the prognostic power of these three genes by performing a survival analysis and a binary classification on multiple gene expression datasets of different groups of patients diagnosed with neuroblastoma. Finally, we discussed the main studies in the literature associating these three genes with neuroblastoma. Our results, in each of these three steps of validation, confirm the prognostic capability of AHCY, DPYLS3, and NME1, and highlight their key role in neuroblastoma prognosis. Our results can have an impact on neuroblastoma genetics research: biologists and medical researchers can pay more attention to the regulation and expression of these three genes in patients having neuroblastoma, and therefore can develop better cures and treatments which can save patients' lives.

Keywords: Endocrine neoplasia; Neuro-oncology; Neuroblastoma; Pediatric cancers; Prognostic signatures; Review; Scientific literature; Signatures; Survey.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Forest plot of the association between associating low/high gene expression with and all-cause mortality. Forest plots displaying the results from the meta-analysis for the three genes considered separately, i.e. AHCY (A), DPYSL3 (B), NME1 (C), and for the score which combines the expression-based ranks of the three genes, considering the reversed rank for DPYSL3 since it showed RRs <1. Results from both fixed- (common) and random-effects models are reported. Abbreviations: RR, Risk Ratio; CI, Confidence Interval

References

    1. Cleveland Clinic. Neuroblastoma. https://my.clevelandclinic.org/health/diseases/14390-neuroblastoma. Accessed 5 Aug 2022.
    1. American Cancer Society. What causes neuroblastoma? https://www.cancer.org/cancer/neuroblastoma/causes-risks-prevention/what.... Accessed 5 Aug 2022.
    1. Sanz-Pamplona R, Berenguer A, Cordero D, Riccadonna S, Solé X, Crous-Bou M, et al. Clinical value of prognosis gene expression signatures in colorectal cancer: a systematic review. PLoS ONE. 2012;7(11):e48877. doi: 10.1371/journal.pone.0048877. - DOI - PMC - PubMed
    1. Chung W, Eum HH, Lee HO, Lee KM, Lee HB, Kim KT, et al. Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. Nat Commun. 2017;8(1):1–12. doi: 10.1038/ncomms15081. - DOI - PMC - PubMed
    1. Szyf M. DNA methylation signatures for breast cancer classification and prognosis. Genome Med. 2012;4(3):1–12. doi: 10.1186/gm325. - DOI - PMC - PubMed
Cite

AltStyle によって変換されたページ (->オリジナル) /